Advising patients who seek complementary and alternative medical therapies for cancer

Annals of Internal Medicine

Volumn 137, Issue 11, 2002, Pages 889-903

  Weiger, Wendy A ^a,b,c,d   Smith, Michael ^a,b,c   Boon, Heather ^a,b,c   Richardson, Mary Ann ^a,b,c   Kaptchuk, Ted J ^a,b,c   Eisenberg, David M ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; FAT; HERBACEOUS AGENT; PHYTOESTROGEN; RETINOL;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CANCER THERAPY; DIET; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; EXERCISE; FAT INTAKE; HERBAL MEDICINE; HUMAN; MASSAGE; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE CANCER; VITAMIN SUPPLEMENTATION;

EID: 0037016062     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-11-200212030-00010     Document Type: Article

References (204)

1. Kaptchuk TJ, Eisenberg DM. Varieties of healing. 2: A taxonomy of unconventional healing practices. Ann Intern Med. 2001;135:196-204. [PMID: 11487487]
2. Cohen MH, Eisenberg DM. Potential physician malpractice liability associated with complementary and integrative medical therapies. Ann Intern Med. 2002;136:596-603. [PMID: 11955028]
3. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID: 8721797]
4. Wu AH, Pike MC, Stram DO. Meta-analysis: Dietary fat intake, serum esrrogen levels, and the risk of breast cancer. J Natl Cancer Inst. 1999;91:529-34. [PMID: 10088623]
5. Chlebowski RT, Rose D, Buzzard IM, Blackburn GL, Insull W Jr, Grosvenor M, et al. Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS). Breast Cancer Res Treat. 1992;20:73-84. [PMID: 1554890]
6. Holmes MD, Stampfer MJ, Colditz GA, Rosner B, Hunter DJ, Willett WC. Dietary factors and the survival of women with breast carcinoma. Cancer. 1999; 86:826-35. [PMID: 10463982]
7. Yip I, Aronson W, Heber D. Nutritional approaches to the prevention of prostate cancer progression. Adv Exp Med Biol. 1996;399:173-81. [PMID: 8937557]
8. Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer Causes Control. 1999;10:245-51. [PMID: 10482482]
9. Bairati I, Meyer F, Fradet Y, Moore L. Dietary fat and advanced prostate cancer. J Urol. 1998; 159:1271-5. [PMID: 9507851]
10. Kim DJ, Gallagher RP, Hislop TG, Holowaty EJ, Howe GR, Jain M, et al. Premorbid diet in relation to survival from prostate cancer (Canada). Cancer Causes Control. 2000;11:65-77. [PMID: 1068073]
11. Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:719-25. [PMID: 12163324]
12. Sattilaro AJ, Monte T. Recalled by Life. Boston: Houghton Mifflin; 1982.
13. Brown V, Stayman S, Kushi M. Macrobiotic Miracle: How a Vermont Family Overcame Cancer. New York: Japan Publications; 1985.
14. Kushi M, Jack A. The Cancer Prevention Diet: Michio Kushi's Nutritional Blueprint for the Prevention and Relief of Disease. New York: St. Martin's Pr; 1983.
15. Kushi M, Esko E. The Macrobiotic Approach to Cancer: Towards Preventing and Controlling Cancer with Diet and Lifestyle. Garden City Park, NY: Avery Publishing Group; 1991.
16. Adlercreutz H, Höckerstedt K, Bannwart C, Bloigu S, Hämäläinen E, Fotsis T, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem. 1987;27:1135-44. [PMID: 2826899]
17. Carter JP, Saxe GP, Newbold V, Peres CE, Campeau RJ, Bernal-Green L. Hypothesis: Dietary management may improve survival from nutritionally linked cancers based on analysis of representative cases. J Am Coll Nutr. 1993;12:209-26. [PMID: 8409076]
18. Questionable methods of cancer management: "Nutritional" therapies. CA Cancer J Clin. 1993;43:309-19. [PMID: 8364770]
19. Wissel PS, Denke M, Inturrisi CE. A comparison of the effects of a macrobiotic diet and a Western diet on drug metabolism and plasma lipids in man. Eur J Clin Pharmacol. 1987;33:403-7. [PMID: 3443147]
20. Unconventional Cancer Treatments, OTA-H-405. U.S. Congress, Office of Technology Assessment. Washington, DC: U.S. Government Printing Office; 1990.
21. Weitzman S. Alternative nutritional cancer therapies. Int J Cancer Suppl. 1998;11:69-72. [PMID: 9876483]
22. Bowman BB, Kushner RF, Dawson SC, Levin B. Macrobiotic diets for cancer treatment and prevention. J Clin Oncol. 1984;2:702-11. [PMID: 6374060]
23. Fletcher RH, Fairfield KM. Vitamin Supplementation in Disease Prevention. 2001. Accessed on 10 August 2001 at www.uptodate.com.
24. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Food and Nutrition Bank. Institute of Medicine. Washington, DC: National Academy Pr; 2001.
25. Marcus R, Coulston AM. Fat-soluble vitamins: Vitamins A, K, and E. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th Ed. New York: McGraw-Hill; 1996:1573-90.
26. Meydani SN, Meydani M, Blumberg JB, Leka LS, Siber G, Loszewski R, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA. 1997;277:1380-6. [PMID: 9134944]
27. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with α-tocopherol and β-carorene: Incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90:440-6. [PMID: 9521168]
28. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-9. [PMID: 8602179]
29. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88:1550-9. [PMID: 8901853]
30. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. 1993;11:1216-22. [PMID: 8391063]
31. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-35. [PMID: 8127329]
32. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-5. [PMID: 8602180]
33. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301:687-90. [PMID: 384241]
34. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985;312:137-41. [PMID: 3880867]
35. Wilkinson IB, Megson IL, MacCallum H, Sogo N, Cockcroft JR, Webb DJ. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol. 1999;34:690-3. [PMID: 10547085]
36. Bordia A, Verma SK. Effect of vitamin C on platelet adhesiveness and platelet aggregation in coronary artery disease patients. Clin Cardiol. 1985;8:552-4. [PMID: 4053437]
37. Calzada C, Bruckdorfer KR, Rice-Evans CA. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis. 1997;128:97-105. [PMID: 9051202]
38. Bordia AK. The effect of vitamin C on blood lipids, fibrinolytic activity and platelet adhesiveness in patients with coronary artery disease. Atherosclerosis. 1980;35:181-7. [PMID: 7352955]
39. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes Tables: Vitamins. 2002. Accessed at www.iom.edu/IOM/IOMHome.nsf/Pages/Food+and+Nutrition+Board on 5 February 2002.
40. Williams JC, Forster LA, Tull SP, Wong M, Bevan RJ, Ferns GA. Dietary vitamin E supplementation inhibits thrombin-induced platelet aggregation, but not monocyte adhesiveness, in patients with hypercholesterolaemia. Int J Exp Pathol. 1997;78:259-66. [PMID: 9505937]
41. Herman C, Adlercreutz T, Goldin BR, Gorbach SL, Höckerstedt KA, Watanabe S, et al. Soybean phytoestrogen intake and cancer risk. J Nutr. 1995;25:757S-70S.
42. Wiseman H. Role of dietary phyto-oestrogens in the protection against cancer and heart disease. Biochem Soc Trans. 1996;24:795-800. [PMID: 8878850]
43. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer. 1997;27:31-40. [PMID: 8970179]
44. Wang C, Kurzer MS. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr Cancer. 1998;31:90-100. [PMID: 9770719]
45. Adlercreutz H, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol. 1993;44:147-53. [PMID: 8382517]
46. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995;147:295-302. [PMID: 7490559]
47. Mousavi Y, Adlercreutz H. Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steroids. 1993;58:301-4. [PMID: 8212077]
48. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: A critical review of the literature. J Nutr. 2001;131:3095S-108S. [PMID: 11694655]
49. Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002;94:1166-74. [PMID: 11920488]
50. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst. 1998;90:1830-5. [PMID: 9839524]
51. Duncan AM, Merz BE, Xu X, Nagel TC, Phipps WR, Kurzer MS. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab. 1999;84:192-7. [PMID: 9920082]
52. Martini MC, Dancisak BB, Haggans CJ, Thomas W, Slavin JL. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer. 1999;34:133-9. [PMID: 10578479]
53. Persky VW, Turyk ME, Wang L, Freels S, Chatterton R Jr, Barnes S, et al. Effect of soy protein on endogenous hormones in postmenopausal women. Am J Clin Nutr. 2002;75:145-53. [PMID: 11756072]
54. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. 1999;84:3479-84. [PMID: 10522983]
55. Baird DD, Umbach DM, Lansdell L, Hughes CL, Setchell KD, Weinberg CR, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab. 1995;80:1685-90. [PMID: 7745019]
56. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2000;7:236-42. [PMID: 10914616]
57. Habito RC, Montalto J, Leslie E, Ball MJ. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males. Br J Nutr. 2000;84:557-63. [PMID: 11103227]
58. Nagata C, Takatsuka N, Shimizu H, Hayashi H, Akamatsu T, Murase K. Effect of soymilk consumption on serum estrogen and androgen concentrations in Japanese men. Cancer Epidemiol Biomarkers Prev. 2001;10:179-84. [PMID: 11303585]
59. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592-5. [PMID: 3106339]
60. Markovits J, Linassier C, Fossé P, Couprie J, Pierre J, Jacquemin-Sablon A, et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 1989;49:5111-7. [PMID: 2548712]
61. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer. 1997;28:236-47. [PMID: 9343831]
62. Santibáñez JF, Navarro A, Martínez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res. 1997;17:1199-204. [PMID: 9137471]
63. Santell RC, Kieu N, Helferich WG. Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J Nutr. 2000;130:1665-9. [PMID: 10867033]
64. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993;90:2690-4. [PMID: 7681986]
65. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997;57:2916-21. [PMID: 9230201]
66. Li D, Yee JA, McGuire MH, Murphy PA, Yan L. Soybean isoflavones reduce experimental metastasis in mice. J Nutr. 1999;129:1075-8. [PMID: 10222402]
67. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and post-menopausal women. Cancer Epidemiol Biomarkers Prev. 1996;5:785-94. [PMID: 8896889]
68. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84:4017-24. [PMID: 10566643]
69. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61:5045-50. [PMID: 11431339]
70. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002; 62:2474-7. [PMID: 11980635]
71. Williams JK, Clarkson TB. Dietary soy isoflavones inhibit in-vivo constrictor responses of coronary arteries to collagen-induced platelet activation. Coron Artery Dis. 1998;9:759-64. [PMID: 9919424]
72. Boon H, Smith M. The Botanical Pharmacy: The Pharmacology of 47 Common Herbs. Kingston, Ontario, Canada: Quarry Pr; 1999.
73. Sovak M, Seligson AL, Konas M, Hajduch M, Dolezal M, Machala M, et al. Herbal composition PC-SPES for management of prostate cancer: Identification of active principles. J Natl Cancer Inst. 2002;94:1275-81. [PMID: 12208892]
74. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000;20:2653-8. [PMID: 10953339]
75. Gutendorf B, Westendorf J. Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology. 2001;166:79-89. [PMID: 11518614]
76. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785-91. [PMID: 9738085]
77. Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology. 2001;57:122-6. [PMID: 1164156]
78. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int. 2000;85:481-5. [PMID: 10691828]
79. Moyad MA, Pienta KJ, Montie JE. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology. 1999;54:319-23; discussion 323-4. [PMID: 10443732]
80. de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, et al. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol. 2000;164:1229-34. [PMID: 10992371]
81. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595-603. [PMID: 11054432]
82. Darzynklewicz Z, Traganos F, Wu JM, Chen S. Chinese herbal mixture PC SPES in treatment of prostate cancer (review). Int J Oncol. 2000;17:729-36. [PMID: 10995884]
83. Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: Identification of activity pathways in prostate carcinoma. Cancer Res. 2002;62:3920-4. [PMID: 12124319]
84. de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. Effects of a phytotherapeutlc agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients. BJU Int. 1999;84:845-50. [PMID: 10532984]
85. Halicka HD, Ardelt B, Juan G, Mittelman A, Chen S, Traganos F, et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. Int J Oncol. 1997;11:437-48.
86. Hsieh T, Chen SS, Wang X, Wu JM. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int. 1997;42:535-44. [PMID: 9247711]
87. Kubota T, Hisatake J, Hisatake Y, Said JW, Chen SS, Holden S, et al. PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate. 2000;42:163-71. [PMID: 10639186]
88. Hsieh TC, Ng C, Chang CC, Chen SS, Mitdeman A, Wu JM. Induction of apoptosis and down-regulation of bcl-6 in mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol. 1998;13:1199-202. [PMID: 9824631]
89. Ikezoe T, Chen SS, Heber D, Taguchi H, Koeffler HP. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate. 2001;49:285-92. [PMID: 11746275]
90. Awad AB, Fink CS, Williams H, Kim U. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev. 2001;10:507-13. [PMID: 11916349]
91. Small EJ, Kantoff P, Weinberg VK, Nguyen S, Smith M, Bubley GJ, et al. A prospective multicenter randomized trial of the herbal supplement, PC-SPES vs. diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa) [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Orlando, Florida, 18-21 May 2002. 2002;21:A709.
92. Davis NB, Nahlik L, Vogelzang NJ. Does PC-SPES interact with warfarin? J Urol. 2002;167:1793. [PMID: 11912419]
93. Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES [Letter]. N Engl J Med. 2001;345:1213-4. [PMID: 11642247]
94. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998;16:3649-55. [PMID: 9817287]
95. Leitner SP, Rothkopf MM, Haverstick L, Rodman DD, Michaelson RA. Two phase II studies of oral dry shark cartilage powder (SCP) in patients (pts) with either metastatic breast or prostate cancer refractory to standard treatment [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Los Angeles, California, 16-19 May 1998. 1998;17:A240.
96. Rosenbluth RJ, Jennis AA, Cantwell S, DeVries J. Oral shark cartilage in the treatment of patients with advanced primary brain tumors. A phase II pilot study [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Atlanta, Georgia, 15-18 May 1999. 1999;18:A554.
97. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, et al. Neovastat (/E-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol. 2002;13:1259-63. [PMID: 12181250]
98. Holt S. Nutriceuticals and augiogenesis: New therapeutic horizons. Alternative & Complementary Therapies. 1995;1:243-7
99. Rivière M, Alaoui-Jamali M, Falardeau P, Blasecki J, Dupont É. Neovastat: An inhibitor of angiogenesis with anti-cancer activity [Abstract]. Proceedings of the American Association for Cancer Research. New Orleans, Louisiana, 28 March-I April 1998. 1998;39:46.
100. Cartilage. 1999. Accessed at www.sph.uth.tmc.edu:8052/utcam/thetapies/crtlg.htm on 3 January 2000.
101. MacKinnon S. Shark cartilage. In: Chandler F, ed. Herbs: Everyday Reference for Health Professionals. Ottawa, Ontario, Canada: Canadian Pharmacists Association/Canadian Medical Association; 2000:191-2.
102. Dvorkin L, Le T, Gerzenshtein S. Shark Cartilage. 1999. Accessed at www.mcp.edu/herbal/ on 3 January 2000.
103. NIH Consensus Conference. Acupuncture. NIH Consensus Development Panel on Acupuncture. JAMA. 1998;280:1518-24. [PMID: 9809733]
104. Dundee JW, Ghaly RG, Fitzpatrick KT, Lynch GA, Abram WP. Acupuncture to prevent cisplatin-associated vomiting [Letter]. Lancet. 1987;1:1083. [PMID: 2883410]
105. Shen J, Wenget NS, Glaspy JA, Hays RD, Elliott M, Choi C, et al. Adjunct antiemesis electroacupuncture in stem cell transplantation [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Denver, Colorado, 17-20 May 1997. 1997;16:A148.
106. Price H, Lewith G, Williams C. Acupressure as an antiemeric in cancer chemotherapy. Complementary Medical Research. 1991;5:93-4.
107. McMillan C, Dundee JW, Abram WP. Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs. Br J Cancer. 1991;64:971-2. [PMID: 1834156]
108. Shen J, Wenger N, Glaspy J, Hays RD, Albert PS, Choi C, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis. A randomized controlled trial. JAMA. 2000;284:2755-61. [PMID: 11105182]
109. Pearl ML, Fischer M, McCauley DL, Valea FA, Chalas E. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs. 1999;22:307-11. [PMID: 10452208]
110. Vickers AJ. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. J R Soc Med. 1996;89:303-11. [PMID: 8758186]
111. Singh CV. Role of acupuncture analgesia for intractable pain in malignancy. J Indian Med Assoc. 1978;11:109-9.
112. Mann F, Bowsher D, Mumford J, Lipton S, Miles J. Treatment of intractable pain by acupuncture. Lancet. 1973;2:57-60. [PMID: 4123617]
113. Peng AT, Omura Y, Cheng HC, Blancato LS. Acupuncture for relief of chronic pain and surgical analgesia. Am Surg. 1974;40:50-3. [PMID: 4808622]
114. Rico RC, Tradnowski RJ. Studies with electro-acupuncture. J Med. 1982;13:247-51. [PMID: 6217269]
115. Wen HL Cancer pain treated with acupuncture and electrical stimulation. Modern Medicine of Asia. 1977;13:12-6.
116. Filshie J, Redman D. Acupuncture and malignant pain problems. Eur J Surg Oncol. 1985;11:389-94. [PMID: 4065352]
117. Filshie J. The non-drug treatment of neuralgic and neuropathic pain of malignancy. Cancer Surv. 1988;7:161-93. [PMID: 2454739]
118. Alimi D, Rubino C, Leandri EP, Brulé SF. Analgesic effects of auricular acupuncture for cancer pain [Letter]. J Pain Symptom Manage. 2000;19:81-2. [PMID: 10766574]
119. Kaptchuk TJ. Acupuncture: Theory, efficacy, and practice. Ann Intern Med. 2002;136:374-83. [PMID: 11874310]
120. Peuker ET, White A, Ernst E, Pera F, Filler TJ. Traumatic complications of acupuncture. Therapists need to know human anatomy. Arch Fam Med. 1999;8:553-8. [PMID: 10575398]
121. MacPherson H. Fatal and adverse events from acupuncture: Allegation, evidence, and the implications. J Altern Complement Med. 1999;5:47-56. [PMID: 10100030]
122. Ahles TA, Tope DM, Pinkson B, Walch S, Hann D, Whedon M, et al. Massage therapy for patients undergoing autologous bone marrow transplantation. J Pain Symptom Manage. 1999;18:157-63. [PMID: 10517036]
123. Lawvere S. The effect of massage therapy in ovarian cancer patients. In: Rich GJ, ed. Massage Therapy: The Evidence for Practice. Edinburgh: Mosby; 2002:57-83.
124. Wilkie DJ, Kampbell J, Cutshall S, Halabisky H, Harmon H, Johnson LP, et al. Effects of massage on pain intensity, analgesics and quality of life in patients with cancer pain: A pilot study of a randomized clinical trial conducted within hospice care delivery. Hosp J. 2000;15:31-53. [PMID: 11315685]
125. Grealish L, Lomasney A, Whiteman B. Foot massage. A nursing intervention to modify the distressing symptoms of pain and nausea in patients hospitalized with cancer. Cancer Nuts. 2000;23:237-43. [PMID: 10851775]
126. Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology. 1998;31:56-64. [PMID: 9664269]
127. Johansson K, Albertsson M, Ingvar C, Ekdahl C. Effects of compression bandaging with or without manual lymph drainage treatment in patients with postoperative arm lymphedema. Lymphology. 1999;32:103-10. [PMID: 10494522]
128. Curties D. Massage Therapy and Cancer. Toronto, Ontario, Canada: Sutherland-Chan Publications; 1998.
129. Yeo TC, Choo MH, Tay MB. Massive haematoma from digital massage in an anticoagulated patient: A case report. Singapore Med J. 1994;35:319-20. [PMID: 7997915]
130. Trotter JF. Hepatic hematoma after deep tissue massage [Letter]. N Engl J Med. 1999;341:2019-20. [PMID: 10617400]
131. Mikhail A, Reidy JF, Taylor PR, Scoble JE. Renal artery embolization after back massage in a patient with aortic occlusion. Nephrol Dial Transplant. 1997;12:797-8. [PMID: 9141017]
132. Kerr HD. Ureteral stent displacement associated with deep massage. WMJ. 1997;96(12):57-8. [PMID: 9433179]
133. Linn MW, Linn BS, Harris R. Effects of counseling for late stage cancer patients. Cancer. 1982;49:1048-55. [PMID: 7059922]
134. Forester B, Kornfeld DS, Fleiss JL. Psychotherapy during radiotherapy: Effects on emotional and physical distress. Am J Psychiatry. 1985;142:22-7. [PMID: 3966583]
135. Telch CF, Telch MJ. Group coping skills instruction and supportive group therapy for cancer patients: A comparison of strategies. J Consult Clin Psychol. 1986;54:802-8. [PMID: 3794024]
136. Bindemann S, Soukop M, Kaye SB. Randomised controlled study of relaxation training. Eur J Cancer. 1991;27:170-4. [PMID: 1827283]
137. Walker LG, Walker MB, Ogston K, Heys SD, Ah-See AK, Miller ID, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer. 1999;80:262-8. [PMID: 10390006]
138. Speca M, Carlson LE, Goodey E, Angen M. A randomized, wait-list controlled clinical trial: The effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med. 2000;62:613-22. [PMID: 11020090]
139. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized prospective outcome study. Arch Gen Psychiatry. 1981;38:527-33. [PMID: 7235853]
140. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry. 1990;47:720-5. [PMID: 2378543]
141. Greer S, Moorey S, Baruch JD, Watson M, Robertson BM, Mason A, et al. Adjuvant psychological therapy for patients with cancer: A prospective randomised trial. BMJ. 1992;304:675-80. [PMID: 1472184]
142. Goodwin PJ, Leszcz M, Ennis M, Koopmans J, Vincent L, Guther H, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345:1719-26. [PMID: 11742045]
143. Fukui S, Kugaya A, Okamura H, Kamiya M, Koike M, Nakanishi T, et al. A psychosocial group intervention for Japanese women with primary breast carcinoma. A randomized controlled trial. Cancer. 2000;89:1026-36. [PMID: 10964333]
144. Edelman S, Bell DR, Kidman AD. A group cognitive behaviour therapy programme with metastatic breast cancer patients. Psychooncology. 1999;8:295-305. [PMID: 10474848]
145. Classen C, Buder LD, Koopman C, Miller E, DiMiceli S, Giese-Davis J, et al. Supportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial. Arch Gen Psychiatry. 2001;58:494-501. [PMID: 11343530]
146. Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med. 1983;45:333-9. [PMID: 6622622]
147. Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: A controlled clinical trial. Pain. 1992;48:137-46. [PM1D: 1350338]
148. Syrjala KL, Donaldson GW, Davis MW, Kippes ME, Carr JE. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: A controlled clinical trial. Pain. 1995;63:189-98. [PMID: 8628584]
149. Sloman R, Brown P, Aldana E, Chee E. The use of relaxation for the promotion of comfort and pain relief in persons with advanced cancer. Contemp Nurse. 1994;3:6-12. [PMID: 8136641]
150. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2:888-91. [PMID: 2571815]
151. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993;50:681-9. [PMID: 8357293]
152. Kuchler T, Henne-Bruns D, Rappat S, Graul J, Hoist K, Williams JI, et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: Survival results of a trial. Hepatogastroenterology. 1999;46:322-35. [PMID: 10228816]
153. Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8:356-64. [PMID: 2299375]
154. Ratcliffe MA, Dawson AA, Walker LG. Eysenck Personality Inventory L-scores in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Psychooncology. 1995;4:39-45.
155. Walker LG. Hypnosis and cancer: Host defences, quality of life and survival. Contemporary Hypnosis. 1998;15:34-8.
156. Ilnyckyj A, Farber J, Cheang MC, Weinerman BH. A randomized controlled trial of psychotherapeutic intervention in cancer patients. Annals of the Royal College of Physicians and Surgeons of Canada. 1994;27:93-6.
157. Cunningham AJ, Edmonds CV, Jenkins GP, Pollack H, Lockwood GA, Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology. 1998;7:508-17. [PMID: 9885092]
158. Edelman S, Lemon J, Bell DR, Kidman AD. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology. 1999;8:474-81. [PMID: 10607980]
159. Walker LG, Heys SD, Walker MB, Ogston K, Miller ID, Hutcheon AW, et al. Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer. Eur J Cancer. 1999;35:1783-8. [PMID: 10673992]
160. Smith M, Boon HS. Counseling cancer patients about herbal medicine. Patient Education and Counseling. 1999;38:109-20.
161. Essiac. 1999. Accessed at www.sph.uth.tmc.edu:8052/utcam/therapies/essic.htm on 3 January 2000.
162. Stelling K. Essiac. In: Chandler F, ed. Herbs: Everyday Reference for Health Professionals. Ottawa, Ontario, Canada: Canadian Pharmacists Association/Canadian Medical Association; 2000:110-11.
163. Duda RB, Zhong Y, Navas V, Li MZ, Toy BR, Alavarez JG. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol. 1999;72:230-9. [PMID: 10589039]
164. Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause. 2002;9:145-50. [PMID: 11875334]
165. Punnonen R, Lukola A. Oestrogen-like effect of ginseng. Br Med J. 1980;281:1110. [PMID: 7191760]
166. Hopkins MP, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol. 1988;159:1121-2. [PMID: 3189445]
167. Ernst E. St John's Wort supplements endanger the success of organ transplantation. Arch Surg. 2002;137:316-9. [PMID: 11888457]
168. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort [Letter]. Lancet. 2000;355:547-8. [PMID: 10683007]
169. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247-9. [PMID: 12189228]
170. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc. 2000;75:933-42. [PMID: 10994829]
171. Frei B. Reactive oxygen species and antioxidant vitamins: Mechanisms of action. Am J Med. 1994;97(Suppl 3A):5S-13S; discussion 22S-28S. [PMID: 8085584]
172. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology (Huntingt). 1999;13:1003-8; discussion 1008, 1011-2. [PMID: 10442346]
173. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999;4:304-29. [PMID: 10559547]
174. DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th Ed. Philadelphia: Lippincott-Raven Publishers; 1997.
175. Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. Br J Cancer. 1988;57:416-7. [PMID: 3390377]
176. Kucera H, Micksche M. [Immunologic stimulation with vitamin A in advanced cervix cancer]. Fortschr Med. 1982;100:760-3. [PMID: 7084867]
177. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983;10:53-5. [PMID: 6340204]
178. Cascinu S, Cordelia L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. J Clin Oncol. 1995;13:26-32. [PMID: 7799029]
179. Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantù MG, Cavaletti G. Neutotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer. 1996;6:415-9.
180. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial. Ann Oncol. 1997;8:569-73. [PMID: 9261526]
181. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478-83. [PMID: 12177109]
182. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, et al. increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53:43-6. [PMID: 8570130]
183. Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, et al. A randomized study of chemotherapy with cisplarin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997;23:15-9. [PMID: 937934t]
184. Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35:1688-92. [PMID: 10674014]
185. Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group. Cancer Invest. 1992;10:1-9. [PMID: 1735009]
186. Salcamoto K, Sakka M. Reduced effect of irradiation on normal and malignant cells irradiated in vivo in mice pretreated with vitamin E. Br J Radiol. 1973;46:538-40. [PMID: 4718295]
187. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha). 1998;43:505-6. [PMID: 9821311]
188. Kågerud A, Peterson HI. Tocopherol in irradiation of experimental neoplasm. Influence of dose and administration. Acta Radiol Oncol. 1981;20:97-100. [PMID: 6270974]
189. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβ. Nat Med. 1997;3:1233-41. [PMID: 9359698]
190. Teicher BA, Schwartz JL, Holden SA, Ara G, Northey D. In vivo modulation of several anticancer agents β-carotene. Cancer Chemother Pharmacol. 1994:34:235-41. [PMID: 8004757]
191. Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer. 1999;80:629-38. [PMID: 10360638]
192. Connors TA. Protection against the toxicity of alkylating agents by thiols: The mechanism of protection and its relevance to cancer chemotherapy. A review. Eur J Cancer. 1966;2:293-305. [PMID: 5342910]
193. Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol. 1998;25:525-37. [PMID: 9783592]
194. Physicians' Desk Reference. 55th Ed. Montvale, NJ: Medical Economics; 2001.
195. Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions. Report of the U.S. Preventive Services Task Force. U.S. Preventive Services Task Force. Baltimore: Williams & Wilkins; 1989:388.
196. Giese S, Hentz VR. Posterior interosseous syndrome resulting from deep tissue massage [letterl. Plast Reconstr Surg. 1998;102:1778-9. [PMID: 9774065]
197. Herskovitz S, Strattch B, Gordon MJ. Shiatsu massage-induced injury of the median recurrent motor branch [Letter]. Muscle Nerve. 1992;15:1215. [PMID: 1406783]
198. MacVicar MG, Winningham ML, Nickel JL. Effects of aerobic interval training on cancer patients' functional capacity. Nurs Res. 1989;38:348-51. [PMID: 2587289]
199. Mock V, Dow KH, Meares CJ, Grimm PM, Dienemann JA, Haisfield-Wolfe ME, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 1997;24:991-1000. [PMID: 9243585]
200. Dimeo F, Fetscher S, Lange W, Mertelsmann R, Keul J. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood. 1997;90:3390-4. [PMID: 9345021]
201. Dimeo FC, Stieglitz RD, Novelli-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85:2273-7. [PMID: 10326708]
202. Segal R, Evans W, Johnson D, Smith J, Colletta S, Gayton J, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: Results of a randomized controlled trial. J Clin Oncol. 2001;19: 657-65. [PMID: 11157015]
203. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135:594-600. [PMID: 11601931]
204. Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med. 1997;127:61-9.[PMID: 9214254]